Dengue fever – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dengue fever – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of the Dengue Vaccine Qdenga on Antibody Levels in Swedish Travelers https://clinicaltrials.eu/trial/study-on-the-effects-of-the-dengue-vaccine-qdenga-on-antibody-levels-in-swedish-travelers/ Wed, 29 Apr 2026 15:05:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-the-dengue-vaccine-qdenga-on-antibody-levels-in-swedish-travelers/ This clinical trial is focused on studying the effects of a vaccine called Qdenga, which is used to prevent dengue fever. Dengue fever is a disease caused by a virus transmitted through mosquito bites, and it can lead to symptoms like high fever, severe headache, and joint pain. The Qdenga vaccine is a live, attenuated vaccine, meaning it contains a weakened form of the virus that helps the body build immunity without causing the disease.

The purpose of this study is to understand how the Qdenga vaccine affects the levels of certain antibodies in the blood. Antibodies are proteins made by the immune system to help fight infections. Specifically, the study will look at whether the vaccine causes increased levels of antibodies that might react with other viruses similar to dengue, such as the viruses that cause tick-borne encephalitis (TBEV), yellow fever (YFV), Zika (ZIKV), and Japanese encephalitis (JE). This will be assessed by comparing antibody levels before and 90 days after receiving two doses of the vaccine.

Participants in the study will receive two doses of the Qdenga vaccine. The study will monitor the participants over a period to observe any changes in antibody levels. This research aims to provide valuable information on how the vaccine interacts with the immune system, particularly in people who may travel to areas where dengue fever is common. The study is expected to continue until 2027.

]]>